Paper Details

  1. Home
  2. Paper Details

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Author: BaerlocherG M, BrümmendorfT H, FabariusA, GratwohlA, HaferlachC, HehlmannR, HeimD, HossfeldD K, JerominS, KohlbrennerK, KolbH J, KrauseS, LausekerM, MüllerM C, NerlC, NeubauerA, PfirrmannM, ProetelU, SaußeleS, SchlegelbergerB

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study analyzed data from 1551 patients with newly diagnosed chronic myeloid leukemia (CML) who received imatinib (IM) at various doses or in combination with other therapies. The results show that monotherapy with IM400 mg provides a close to normal life expectancy for responders, and survival is more dependent on patient and disease factors than treatment selection.
Paper Details　
Original Abstract of the Article :
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668495/

データ提供：米国国立医学図書館（NLM）

Imatinib for Chronic Myeloid Leukemia: A 10-Year Perspective

This [longitudinal study] explores the [efficacy] of imatinib (IM) as a [first-line treatment] for chronic myeloid leukemia (CML). The authors present 10-year survival data from a [randomized clinical trial], demonstrating [significant survival benefits] for patients receiving IM. The research emphasizes the [impact] of [non-CML determinants] on survival and highlights the [importance] of [early molecular response] in achieving long-term remission.

Imatinib: A [Game Changer] in CML Treatment

This research highlights the [transformative impact] of [imatinib] on the [treatment] of chronic myeloid leukemia (CML). The study demonstrates that [early molecular response] to imatinib is [crucial] for [long-term survival]. This research further underscores the [importance] of [addressing non-CML factors] to [optimize] treatment outcomes for individuals with CML.

Navigating the [Challenges] of [Chronic Disease Management]

Chronic myeloid leukemia is a [serious] condition that requires [ongoing management]. This research highlights the [importance] of [early intervention] and [close monitoring] to [optimize] treatment outcomes for individuals with CML. The study emphasizes the [crucial role] of [non-CML factors] in [influencing] [long-term survival] and the [need for a multidisciplinary approach] to [manage] this [complex] condition.

Dr. Camel's Conclusion

This research demonstrates the [efficacy] of imatinib as a [first-line treatment] for chronic myeloid leukemia. The study highlights the [importance] of [early molecular response] and [managing non-CML factors] to achieve [long-term remission]. Just as a [camel] [adapts] to [changing desert conditions], individuals with CML require [ongoing care] and [personalized treatment] strategies to [manage] this [chronic] condition.
Date :
  1. Date Completed 2017-12-05
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

28804124

DOI: Digital Object Identifier

PMC5668495

Related Literature

Article Analysis
・Effective treatment of chronic myeloid leukemia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.